Redeye comments on today’s news where Freemelt announced its intention to carry out a fully secured ...
Redeye takes a positive stance towards Speqta’s direct share issue despite somewhat lowering its Bas...
Redeye is pleased that Ortoma has received the 510(K) approval from the US FDA regarding the OTS™ Hi...
Redeye comments on Artificial Solutions' Q4 2023 report, which showed a total ARR of SEK63m and a Sa...
Redeye endorses the results from ISAB’s first-in-human clinical study of its PreciseInhale system.
ARR and P&L headline figures known, cash flow and cost items not Timing of guidance upgrade hard to ...
Interview with I-Tech's CFO Magnus Henell Continued growth and profitability in '24 New customer lau...
Redeye reviews the case of Herantis in the wake of progress with clinical candidate HER-096 and H2 r...
USD 9.7m order from a European customer De-risks estimates and diversifies its revenue streams Expec...
Med den fjärde delårsrapporten för 2023 publicerad står det klart att Lucky Games följde upp föregåe...
Redeye cuts its estimates and valuation after Ultimovacs announced that INITIUM failed to show an ef...
Zoomability Int AB (”Zoomability” eller ”Bolaget”) meddelade den 8 mars att Bolaget har signerat ett...
Aspo acquired industrial lubricants distribution businesses from Petrus.
Det fjärde kvartalet blev något mer utmanande för Windon Energy Group AB (”Windon” eller ”Bolaget”) ...
Administer’s H2 was fairly in line with expectations.
Redeye comments on ChromoGenics Q4 2023 report.
Windon Energy Group AB (”Windon” eller ”Bolaget”) har slutit ett avtal med Badger Energy avseende at...
Redeye comments on the interim readout of the phase I study of ALG.
Hög spelaraktivitet Omsättningen i Entropia Universe ökade med över 27,0 procent y-o-y och med 22,5 ...
Redeye believes that INITUM's failure to show improved efficacy of UV1 addition to double CPI therap...
